Merdad Parsey sold $15M of GILD
Chief Medical Officer at GILEAD SCIENCES, INC.. 164,211 shares at an average of $91.92, traded Nov 27, 2024, filed Nov 29, 2024.
Score components
- +15RoleOfficer
- +25Trade size$15.1M at market
- +20Share of holdings soldSold 67% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-24-028232, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 27, 2024 | MOption exercise Common Stock10b5-1 | +57,294 | $57.92 | $3.3M | 156,893 | Nov 29, 2024 |
| Nov 27, 2024 | MOption exercise Common Stock10b5-1 | +88,119 | $65.38 | $5.8M | 245,012 | Nov 29, 2024 |
| Nov 27, 2024 | SOpen-market sale Common Stock10b5-1 | -57,294 | $91.79 | $5.3M | 187,718 | Nov 29, 2024 |
| Nov 27, 2024 | SOpen-market sale Common Stock10b5-1 | -88,119 | $92.00 | $8.1M | 99,599 | Nov 29, 2024 |
| Nov 27, 2024 | SOpen-market sale Common Stock10b5-1 | -5,200 | $91.80 | $477k | 94,399 | Nov 29, 2024 |
| Nov 27, 2024 | SOpen-market sale Common Stock10b5-1 | -3,199 | $91.80 | $294k | 91,200 | Nov 29, 2024 |
| Nov 27, 2024 | SOpen-market sale Common Stock10b5-1 | -10,399 | $92.00 | $957k | 80,801 | Nov 29, 2024 |
| Nov 27, 2024 | MOption exercise Non-qualified Stock Option (Right to Buy)derivative10b5-1 | -57,294 | $0.00 | $0 | 64,376 | Nov 29, 2024 |
| Nov 27, 2024 | MOption exercise Non-qualified Stock Option (Right to Buy)derivative10b5-1 | -88,119 | $0.00 | $0 | 196 | Nov 29, 2024 |
Related signals
Other insiders at GILEAD SCIENCES, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GILEAD SCIENCES, INC. | Daniel Patrick O'Day Chairman & CEO | $2.2M 15,000 shares | -3% | |
| 34Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $436k 3,000 shares | -2% | |
| 27Weak | GILEAD SCIENCES, INC. | Johanna Mercier Chief Comm & Corp Aff Officer | $433k 3,000 shares | -3% | |
| 45Moderate | GILEAD SCIENCES, INC. | Daniel Patrick O'Day Chairman & CEO | $2.2M 15,000 shares | -3% | |
| 24Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $275k 2,500 shares | -1% | |
| 18Weak | GILEAD SCIENCES, INC. | Johanna Mercier Chief Commercial Officer | $331k 3,000 shares | -2% | |
| 38Weak | GILEAD SCIENCES, INC. | Daniel Patrick O'Day Chairman & CEO | $1.1M 10,000 shares | -2% | |
| 25Weak | GILEAD SCIENCES, INC. | Johanna Mercier Chief Commercial Officer | $3.0M 28,000 shares | -20% | |
| 23Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $250k 2,500 shares | -1% | |
| 15Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $266k 2,500 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.